Abstract
The objective of this study was to better understand the implications of the rate of prostate-specific antigen (PSA) changes in prostate carcinoma. We retrospectively calculated PSA doubling times prior to surgery in 62 patients with prostate carcinoma. The calculated values were compared with final pathologic findings and with rates of PSA failure after surgery. PSA values increased during the period of observation in 82.3% of the patients, whereas 17.7% had levels that remained stable. The median calculated PSA doubling time in those with increasing levels was 25.8 months, with doubling times ≤24 months observed in 37.1% of the patients. Stage pT3 disease was more common in patients with PSA doubling times of ≤36 months than in those with doubling times >36 months (P=0.02). Biochemical failure was more common in patients with rapid PSA doubling times (P<0.01). The calculated PSA doubling time prior to radical surgery is significantly associated with the final pathologic findings. Early PSA failure is more common in patients with rapid PSA doubling times prior to radical surgery.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Egawa, S., Arai, Y., Tobisu, K. et al. Use of pretreatment prostate-specific antigen doubling time to predict outcome after radical prostatectomy. Prostate Cancer Prostatic Dis 3, 269–274 (2000). https://doi.org/10.1038/sj.pcan.4500424
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.pcan.4500424
Keywords
This article is cited by
-
Effect of Prior Local Treatment and Prostate-Specific Antigen Kinetics during Androgen-Deprivation Therapy on the Survival of Castration-Resistant Prostate Cancer
Scientific Reports (2019)
-
Active surveillance for favorable-risk prostate cancer: who, how and why?
Nature Clinical Practice Oncology (2007)
-
Active surveillance versus radical treatment for favorable-risk localized prostate cancer
Current Treatment Options in Oncology (2006)
-
Prostate-specific antigen doubling time as a prognostic marker in prostate cancer
Nature Clinical Practice Urology (2005)
-
Active surveillance with selective delayed intervention is the way to manage 'good-risk' prostate cancer
Nature Clinical Practice Urology (2005)